(SANTA CLARA, CALIF., DEC. 17, 2015) — Crown Bioscience, a global drug discovery and development services company that has the world’s largest collection of spontaneously diabetic translational models, is the first research company to establish an ultrasound diagnostic method with its translational model for nonalcoholic steatohepatitis (NASH), the most extreme form of nonalcoholic fatty liver disease (NAFLD). NAFLD is among the most common liver diseases in the western world.
“This innovative method allows for quick, low impact sonographic screening that enables us to actually see disease progression over time,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience. “We can now determine the efficacy of experimental compounds in treating NAFLD including NASH.”
Because this method is reliable and non-invasive, researchers can screen more frequently and efficiently. CrownBio is now able to screen hundreds of models without the need to wait for pathology results to come back. Researchers are also able to track NAFLD and NASH for months at a time without liver biopsies or other invasive measures.
“Our models mirror all aspects of human diabetes and similar syndromes,” said Jim Wang, M.D., senior vice president of cardiovascular and metabolic diseases (CVMD) research at CrownBio. “This is a tremendous advantage when serving pharmaceutical companies working to eradicate cardiovascular and metabolic diseases, particularly NASH, through drug discovery.”
Moreover, researchers are working on establishing disease profiles for glucose, insulin, lipids, liver enzymes, inflammatory and liver biomarkers, to name a few. This improved diagnostic method and disease characterization in the most translatable models available is likely to accelerate the transition of new treatments to the clinic.
In line with its consistent research efforts in diabetes and dysmetabolism, the CVMD group at CrownBio has published several articles in peer-reviewed journals. To access these articles, visit http://www.crownbio.com/metabolic-disease/.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visitwww.crownbio.com.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services
Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Scre...
Crown Bioscience has launched OrganoidXplore, a revolutionary platform for large-scale screening of patient-derived organoids that accelerates preclinical oncology drug discovery. The platform repl...
Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation
Indivumed Services GmbH, a Crown Bioscience company, has received laboratory accreditation from the College of American Pathologists (CAP), highlighting its commitment to excellence in laboratory s...
Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials
Crown Bioscience collaborates with HanX Biopharmaceutical, enabling the progression of HX009 to clinical trials for the treatment of lymphoma. The study demonstrates the efficacy of HX009 in target...
Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed Gmb...